Lithium-associated hair loss is a recognised concern for patients taking this widely prescribed mood stabiliser. Lithium is a first-line treatment for bipolar disorder and treatment-resistant depression in the UK, and whilst it is one of the most extensively studied psychiatric medicines, its side effects — including alopecia — can significantly affect quality of life. Hair thinning linked to lithium may result from direct effects on the hair follicle cycle, lithium-induced hypothyroidism, or nutritional deficiencies. Understanding the causes, how common it is, and what can be done about it is essential for anyone taking lithium long term.

Can Lithium Cause Hair Loss?

Yes, lithium can cause hair loss; alopecia is a recognised adverse effect listed in UK product information, potentially caused by disruption of the hair follicle cycle or indirectly through lithium-induced hypothyroidism.

Experiencing these side effects? Our pharmacists can help you navigate them →

Lithium is a mood-stabilising medication widely prescribed in the UK for bipolar disorder (both treatment and prophylaxis) and as an augmentation strategy in treatment-resistant unipolar depression. It is one of the most extensively studied psychiatric medicines, and its side effect profile is well documented by regulatory bodies including the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA). The UK Summary of Product Characteristics (SmPC) for lithium products such as Priadel and Camcolit lists alopecia as a recognised adverse effect.

Hair loss — medically termed alopecia — is a recognised, though not universal, side effect of lithium therapy. The precise mechanism by which lithium may contribute to hair thinning or shedding is not fully established. One hypothesised pathway involves lithium's inhibition of glycogen synthase kinase-3 beta (GSK-3β), an enzyme thought to play a role in the hair follicle cycle. Disruption to this pathway may interfere with the normal transition between the anagen (growth) and telogen (resting) phases of hair growth, potentially triggering a condition known as telogen effluvium — a diffuse, non-scarring form of hair loss. These mechanisms remain under investigation and should be understood as plausible hypotheses rather than established fact.

Additionally, lithium can affect thyroid function, sometimes causing hypothyroidism, which is itself a well-established cause of hair thinning. In such cases, the hair loss may be an indirect consequence of thyroid disruption rather than a direct effect of the drug on the follicle itself. This distinction is clinically important, as it influences how the problem is investigated and managed. Patients who notice hair changes whilst taking lithium should not assume the cause is straightforward, and a thorough clinical assessment is always warranted.

How Common Is Hair Loss Among Lithium Users?

The precise frequency is unknown; UK SmPC data categorise lithium-associated alopecia as 'frequency not known', and hair loss typically presents as diffuse thinning rather than patterned baldness.

Not sure if this is normal? Chat with one of our pharmacists →

Establishing precise prevalence figures for lithium-associated hair loss is challenging, as studies vary considerably in methodology and patient populations. UK SmPC frequency data for lithium products typically categorise alopecia using the term 'frequency not known', reflecting that reliable population-level estimates are not available from current evidence. Patients and clinicians should be aware that hair thinning or increased shedding is a reported adverse effect, but its true frequency in UK clinical practice remains uncertain.

Hair loss associated with lithium tends to be diffuse rather than patterned, meaning it typically presents as generalised thinning across the scalp rather than receding hairlines or discrete bald patches. This pattern is consistent with telogen effluvium, which can occur weeks to months after a physiological or pharmacological trigger. In many cases, patients may not immediately connect the hair changes to their medication, particularly if the onset is gradual. It is also important to consider other common causes of diffuse hair loss, including androgenetic alopecia and postpartum shedding, before attributing the change solely to lithium.

Certain factors may increase the likelihood of experiencing hair loss whilst on lithium:

• Lithium-induced hypothyroidism: More common in women and those with pre-existing thyroid vulnerability; thyroid function testing (TSH) is the most important initial investigation

• Iron deficiency: Low ferritin is a well-recognised contributor to diffuse hair shedding and should be assessed as part of the initial workup

• Duration of treatment: Longer-term use may be associated with a higher cumulative risk

• Concurrent medications: Some drugs used alongside lithium, such as valproate, are also independently associated with hair loss

Understanding these contributing factors is essential for accurate attribution. Not all hair loss in a person taking lithium is necessarily caused by the lithium itself, and a systematic approach to investigation helps ensure the correct underlying cause is identified and addressed appropriately.

Managing Hair Loss While Taking Lithium

Management begins with thyroid function testing and serum ferritin measurement; if hypothyroidism is confirmed, levothyroxine treatment may resolve hair loss without requiring a change in lithium dose.

If hair loss is suspected to be related to lithium therapy, the first and most important step is not to stop the medication without medical advice. Lithium plays a critical role in mood stabilisation for many patients, and abrupt discontinuation carries significant risks, including rebound mania or severe depressive episodes. Any changes to treatment must be made in close collaboration with a GP or psychiatrist.

From a clinical management perspective, the following steps are typically considered:

• Thyroid function testing: A TSH (thyroid-stimulating hormone) blood test should be performed to rule out lithium-induced hypothyroidism. If hypothyroidism is confirmed, treatment with levothyroxine may resolve or significantly improve hair loss without requiring a change in lithium dose

• Serum lithium levels: Ensuring levels remain within the therapeutic range is important. UK practice, as reflected in the BNF and NICE guidance, typically uses a range of 0.4–1.0 mmol/L, with targets individualised by indication and patient factors (for example, 0.6–0.8 mmol/L for maintenance, and 0.8–1.0 mmol/L in acute mania). Levels above the therapeutic range increase the risk of toxicity and side effects

• Haematological and nutritional assessment: A full blood count (FBC) and serum ferritin should be checked, as iron deficiency is a common and treatable contributor to hair thinning. Further investigations (such as zinc or vitamin D) should be guided by clinical history and examination findings rather than performed routinely

• Dose review: In some cases, a modest reduction in lithium dose — if clinically appropriate and agreed with the prescribing clinician — may reduce hair-related side effects

From a self-care perspective, patients may benefit from using gentle, sulphate-free shampoos, avoiding excessive heat styling, and ensuring a balanced diet rich in protein and micronutrients. Topical minoxidil is sometimes considered by dermatologists in persistent cases; however, its use for telogen effluvium is off-label and evidence in this specific context is limited. It should only be used following specialist advice. Inositol supplementation has been suggested anecdotally in relation to lithium-associated hair loss, but there is insufficient robust evidence to recommend it in routine UK practice; patients should discuss any supplements with their clinician before use, noting that some supplements (including biotin) can interfere with certain laboratory assays, including thyroid function tests.

When to Speak to Your GP or Psychiatrist

Seek prompt medical advice if hair loss is sudden, patchy, or accompanied by symptoms of hypothyroidism; NICE recommends thyroid function monitoring every six months for all patients on long-term lithium.

Whilst some degree of hair thinning can be a manageable and sometimes temporary side effect of lithium, there are circumstances in which it is important to seek prompt medical advice. Patients should contact their GP or psychiatrist if they notice any of the following:

• Sudden or rapid hair loss, particularly if occurring in clumps or patches

• Patchy hair loss (which may suggest alopecia areata, an autoimmune condition unrelated to lithium)

• Scalp inflammation, tenderness, scaling, or pustules, which may indicate scarring alopecia or a fungal infection (such as tinea capitis) requiring prompt assessment by a GP or dermatologist

• Associated symptoms of hypothyroidism, such as unexplained weight gain, fatigue, feeling cold, constipation, or low mood — these warrant thyroid function testing

• Hair loss accompanied by other new symptoms, such as skin changes, nail abnormalities, or swelling, which may indicate a systemic cause

• Significant psychological distress related to hair changes, which may affect treatment adherence

NICE guidance and the BNF recommend regular monitoring for all patients on long-term lithium therapy. Once stable, this includes checking serum lithium levels at least every three months, and thyroid function and renal function (eGFR and electrolytes) every six months. Serum calcium should be checked at least annually. Monitoring should be more frequent if there are clinical concerns or dose changes. These routine reviews provide an ideal opportunity to raise concerns about hair loss and to ensure that any contributing factors — such as thyroid dysfunction — are identified early.

Patients who believe they are experiencing a side effect from lithium are encouraged to report it via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk). This helps regulators monitor the safety of medicines in real-world use.

Patients should feel empowered to discuss side effects openly with their prescribing clinician. Hair loss, whilst not life-threatening, can significantly affect quality of life and self-esteem, and these concerns are entirely valid. A collaborative approach between patient and clinician is essential to finding a management strategy that preserves both mental health stability and overall wellbeing.

Alternatives and Long-Term Considerations

Alternative mood stabilisers such as lamotrigine or quetiapine may be considered if hair loss is persistent and distressing, but switching must be specialist-led given lithium's well-established anti-suicidal and mood-stabilising benefits.

For patients in whom hair loss is persistent, distressing, and clearly attributable to lithium, a discussion about alternative mood-stabilising agents may be appropriate. However, this decision must be made carefully and should always be led by a specialist, weighing the significant benefits of lithium — including its well-established anti-suicidal properties and long-term efficacy in bipolar disorder — against the impact of side effects on quality of life and treatment adherence. Patients should receive clear counselling about the risk of relapse associated with switching or stopping lithium.

Alternative mood stabilisers that may be considered include valproate, lamotrigine, and quetiapine, each with their own distinct side effect profiles and clinical indications. It is important to note that valproate is also associated with hair loss in a proportion of users. Furthermore, valproate carries serious teratogenic risks and is subject to strict MHRA prescribing restrictions: it must not be used in women of childbearing potential unless the conditions of the Pregnancy Prevention Programme (PPP) are met, and initiation must be by a specialist. Patients and prescribers should refer to current MHRA guidance on valproate for full details of these requirements. Lamotrigine is generally considered to have a more favourable tolerability profile and is less commonly associated with hair changes; however, it is more effective for the depressive phase of bipolar disorder than for mania, and its role should be considered in the context of the individual's clinical presentation.

In the long term, patients who continue lithium therapy and experience ongoing hair thinning should be aware that telogen effluvium is often self-limiting once the underlying trigger is identified and managed — for example, through treatment of hypothyroidism or correction of iron deficiency. However, individual responses vary and improvement is not guaranteed in all cases. Regular monitoring, prompt treatment of thyroid dysfunction, and attention to nutritional status can make a meaningful difference. Referral to a dermatologist may be appropriate in cases where hair loss is severe, progressive, or where the diagnosis remains uncertain.

Ultimately, the decision to continue, adjust, or change lithium therapy should always be made on an individual basis, in partnership with the patient and their mental health team. Shared decision-making, informed by up-to-date clinical evidence and the patient's own priorities, remains the cornerstone of good psychiatric care.

Frequently Asked Questions